Влияние COVID-19 на антибиотикорезистентность в педиатрической популяции

Имеются данные о нерациональном использовании противомикробных препаратов в педиатрической популяции в период COVID-19. Это может привести к потенциальному развитию резистентности к антибактериальным лекарственным средствам и увеличению заболеваемости и смертности среди этой уязвимой группы населения. Целью обзорной статьи является изучение влияния COVID-19 на применение противомикробных препаратов и развитие антибиотикорезистентности, а также определение комплекса мер по ее предотвращению. Результаты недавних исследований показывают, что пандемия COVID-19 оказывает прямое и косвенное влияние на развитие резистентности к противомикробным препаратам среди педиатрического населения. Вспышка COVID-19 способствовала выявлению недостатков, присущих системам здравоохранения во всем мире. В этот период использование антибиотиков у больных коронавирусной инфекцией превышало число случаев с присоединенной бактериальной коинфекцией и иными заболеваниями, что свидетельствует о нерациональности антимикробной терапии. Даже в регионах, где программы по рациональной антибиотикотерапии действуют уже давно, были обнаружены недостатки в использовании противомикробных препаратов во время кризиса, обусловленного пандемией COVID-19. Одним из наиболее эффективных методов борьбы с антибиотикорезистентностью является совершенствование подходов в здравоохранении и повышение готовности к вспышкам инфекций. Повышение клинической компетентности медицинских работников, доступность медицинских учреждений, постоянный запас высококачественных и недорогих противомикробных препаратов, вакцин, сокращение времени проведения анализа на COVID-19, осторожное использование антибактериальных средств — вот меры, принятие которых способствует предотвращению заболеваний, обусловленных возникновением лекарственной резистентности. Для установления вышеуказанных мер защиты все заинтересованные стороны (органы здравоохранения, регулирующие агентства, политики, научное сообщество, фармацевтические компании) должны объединяться для совместной работы и достижения результатов.

1. Siddiqui S, Alhamdi HWS, Alghamdi HA. Recent Chronology of COVID-19 Pandemic. Front Public Health. 2022;10:778037. https://doi.org/10.3389/fpubh.2022.778037

2. Bahl A, Mielke N, Johnson S, et al. Severe COVID-19 outcomes in pediatrics: An observational cohort analysis comparing Alpha, Delta, and Omicron variants. Lancet Reg Health Am. 2023;18:100405. https://doi.org/10.1016/j.lana.2022.100405

3. Wei X, Yuan H, Sun Y, et al. Health Services Utilization in China during the COVID-19 Pandemic: Results from a Large-Scale Online Survey. Int J Environ Res Public Health. 2022;19(23):15892. https://doi.org/10.3390/ijerph192315892

4. Кобзева Е.А., Левина Ю.Г. Заболеваемость COVID-19 у детей с астмой и аллергией // Педиатрическая фармакология. — 2022. — Т. 19. — № 1. — С. 78–81. — https://doi.org/10.15690/pf.v19i1.2378

5. Quinn B, Barry OM, Batlivala SP, et al. Changes in Practice/ Outcomes of Pediatric/Congenital Catheterization in Response to the First Wave of COVID. JACC Adv. 2022;100143. https://doi.org/10.1016/j.jacadv.2022.100143

6. Старшинова А.А., Кушнарева Е.А., Малкова А.М. и др. Новая коронавирусная инфекция: особенности клинического течения, возможности диагностики, лечения и профилактики инфекции у взрослых и детей // Вопросы современной педиатрии. — 2020. — Т. 19. — № 2. — С. 123–131. — https://doi.org/10.15690/vsp.v19i2.2105

7. WHO Coronavirus (COVID-19) Dashboard. Available online: https://covid19.who.int. Accessed on December 18, 2022.

8. Caini S, Martinoli C, La Vecchia C, et al. SARS-CoV-2 Circulation in the School Setting: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health. 2022;19(9):5384. https://doi.org/10.3390/ijerph19095384

9. Mataloni F, Colais P, Pinnarelli L, et al. The impact of the SARS COV-2 pandemic on pediatric accesses in ED: A Healthcare Emergency Information System analysis. PLoS One. 2022;17(8):e0272569. https://doi.org/10.1371/journal.pone.0272569

10. Yock-Corrales A, Lenzi J, Ulloa-Gutiérrez R, et al. High rates of antibiotic prescriptions in children with COVID-19 or multisystem inflammatory syndrome: A multinational experience in 990 cases from Latin America. Acta Paediatr. 2021;110(6):1902–1910. https://doi.org/10.1111/apa.15847

11. Moraes VY, Marra AR, Matos LL, et al. Hydroxychloroquine for treatment of COVID-19 patients: a systematic review and metaanalysis of randomized controlled trials. Einstein (Sao Paulo). 2022;20:eRW0045. https://doi.org/10.31744/einstein_journal/2022RW0045

12. Velasco-Arnaiz E, López-Ramos MG, Simó-Nebot S, et al. Pediatric antimicrobial stewardship in the COVID-19 outbreak. Infect Control Hosp Epidemiol. 2021;42(5):642–644. https://doi.org/10.1017/ice.2020.312

13. WHO. Living guidance for clinical management of COVID-19: clinical care, 23 November 2021. World Health Organization; 2021. Available online: https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-2. Accessed on December 03, 2022.

14. COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of Health. Available online: https://www.covid19treatmentguidelines.nih.gov. Accessed on December 03, 2022.

15. Заплатников А.Л., Свинцицкая В.И. COVID-19 и дети // РМЖ. — 2020. — Т. 28. — № 6. — С. 20–22.

16. IDSA. COVID-19 guideline, Part 1: Treatment and management. In: Infectious Diseases Society of America (IDSA). Published by IDSA on 4/11/2020. Last updated 11/21/2022. Available online: https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management. Accessed on December 03, 2022.

17. Особенности клинических проявлений и лечения заболевания, вызванного новой коронавирусной инфекцией (COVID-19) у детей: методические рекомендации. — Версия 2 (03.07.2020). — Министерство здравоохранения Российской Федерации; 2020. Доступно по: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/050/914/original/03062020_дети_COVID-19_v2.pdf. Ссылка активна на 18.12.2022.

18. Rodríguez-Baño J, Rossolini GM, Schultsz C, et al. Key considerations on the potential impacts of the COVID-19 pandemic on antimicrobial resistance research and surveillance. Trans R Soc Trop Med Hyg. 2021;115(10):1122–1129. https://doi.org/10.1093/trstmh/trab048

19. Ashikkali L, Carroll W, Johnson C. The indirect impact of COVID-19 on child health. Paediatr Child Health (Oxford). 2020;30(12):430–437. doi: 10.1016/j.paed.2020.09.004.

20. Appleby G, Papageorgiou V, Horter S, et al. Caregiver perceptions and experiences of paediatric emergency department attendance during the COVID-19 pandemic: A mixed-methods study. PLoS One. 2022;17(11):e0276055. https://doi.org/10.1371/journal.pone.0276055

21. Antúnez-Montes OY, Escamilla MI, Figueroa-Uribe AF, et al. COVID-19 and Multisystem Inflammatory Syndrome in Latin American Children: A Multinational Study. Pediatr Infect Dis J. 2021;40(1):e1–e6. https://doi.org/10.1097/INF.0000000000002949

22. Yazdanpanah S, Ahmadi M, Zare Z, et al. Assessment of Risk Factors and Clinical Outcomes in Hospitalized COVID-19 Patients with Candida spp. Co-infections: Species Distribution and Antifungal Susceptibility Patterns of Isolates. Mycopathologia. 2022;1–12. https://doi.org/10.1007/s11046-022-00694-x

23. Langford BJ, Soucy JR, Leung V, et al. Antibiotic resistance associated with the COVID-19 pandemic: a systematic review and meta-analysis. Clin Microbiol Infect. 2022;S1198-743X(22)00610-3. https://doi.org/10.1016/j.cmi.2022.12.006

24. Soumana A, Samaila A, Moustapha LM, et al. A fatal case of COVID-19 in an infant with severe acute malnutrition admitted to a paediatric ward in Niger. Case Rep Pediatr. 2020;2020:1–3. https://doi.org/10.1155/2020/8847415

25. Kamali Aghdam M, Jafari N, Eftekhari K. Novel coronavirus in a 15-day-old neonate with clinical signs of sepsis, a case report. Infect Dis. 2020;52(6):427–429. https://doi.org/10.1080/23744235.2020.1747634

26. Zhang T, Cui X, Zhao X, et al. Detectable SARS-CoV-2 viral RNA in feces of three children during recovery period of COVID-19 pneumonia. J Med Virol. 2020;92(7):909–914. https://doi.org/10.1002/jmv.25795

27. Ng KF, Bandi S, Bird PW, et al. COVID-19 in Neonates and Infants: Progression and Recovery. Pediatr Infect Dis J. 2020;39(7):140–142. https://doi.org/10.1097/INF.0000000000002738

28. Zhang C, Gu J, Chen Q, et al. Clinical and epidemiological characteristics of pediatric SARS-CoV-2 infections in China: A multicenter case series. PloS Med. 2020;17(6):e1003130. https://doi.org/10.1371/journal.pmed.1003130

29. Zheng F, Liao C, Fan QH, et al. Clinical Characteristics of Children with Coronavirus Disease 2019 in Hubei, China. Curr Med Sci. 2020;40(2):275–280. https://doi.org/10.1007/s11596-020-2172-6

30. Shekerdemian LS, Mahmood NR, Wolfe KK, et al. Characteristics and Outcomes of Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units. JAMA Pediatr. 2020;174(9):868–873. https://doi.org/10.1001/jamapediatrics.2020.1948

31. Peng H, Gao P, Xu Q, et al. Coronavirus disease 2019 in children: Characteristics, antimicrobial treatment, and outcomes. J Clin Virol. 2020;128:104425. https://doi.org/10.1016/j.jcv.2020.104425

32. Nallasamy K, Angurana SK, Jayashree M, et al. Clinical Profile, Hospital Course and Outcome of Children with COVID-19. Indian J Pediatr. 2021;88(10):979–984. https://doi.org/10.1007/s12098-020-03572-w

33. Kelly RS, Lee-Sarwar K, Chen YC, et al. Maternal Inflammatory Biomarkers during Pregnancy and Early Life Neurodevelopment in Offspring: Results from the VDAART Study. Int J Mol Sci. 2022;23(23):15249. https://doi.org/10.3390/ijms232315249

34. Knight GM, Glover RE, McQuaid CF, et al. Antimicrobial resistance and COVID-19: Intersections and implications. Elife. 2021;10:e64139. https://doi.org/10.7554/eLife.64139

35. Kollef MH, Timsit JF, Martin-Loeches I, et al. Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired/ ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane/tazobactam versus meropenem. Crit Care. 2022;26(1):373. https://doi.org/10.1186/s13054-022-04192-w

36. Hu Q, Chen J, Sun S, Deng S. Mortality-Related Risk Factors and Novel Antimicrobial Regimens for Carbapenem-Resistant Enterobacteriaceae Infections: A Systematic Review. Infect Drug Resist. 2022;15:6907–6926. https://doi.org/10.2147/IDR.S390635

37. Frost I, Craig J, Joshi J, et al. Access barriers to antibiotics. Washington, DC: Center for Disease Dynamics. Economics & Policy. 2019. Available online: https://cddep.org/wp-content/uploads/2019/04/AccessBarrierstoAntibiotics_CDDEP_FINAL.pdf. Accessed on December 03, 2022.

38. Kelesidis T, Falagas ME. Substandard/counterfeit antimicrobial drugs. Clin Microbiol Rev. 2015;28(2):443–464. https://doi.org/10.1128/CMR.00072-14

39. Feldman C, Anderson R. The role of co-infections and secondary infections in patients with COVID-19. Pneumonia. 2021;13(1):5. https://doi.org/10.1186/s41479-021-00083-w

40. Pruthi HS. When to Initiate Antifungal Treatment in COVID-19 Patients with Secondary Fungal Co-infection. Curr Clin Microbiol Rep. 2022;9(4):60–68. doi: 10.1007/s40588-022-00184-0.

41. Spigaglia P. Clostridioides difficile infection (CDI) during the COVID-19 pandemic. Anaerobe. 2022;102518. https://doi.org/10.1016/j.anaerobe.2022.102518

42. Bhatt PJ, Shiau S, Brunetti L, et al. Risk Factors and Outcomes of Hospitalized Patients With Severe Coronavirus Disease 2019 (COVID-19) and Secondary Bloodstream Infections: A Multicenter Case-Control Study. Clin Infect Dis. 2021;72(12):e995–e1003. https://doi.org/10.1093/cid/ciaa1748

43. Jones B, Woolfenden S, Pengilly S, et al. COVID-19 pandemic: The impact on vulnerable children and young people in Australia. J Paediatr Child Health. 2020;56(12):1851–1855. https://doi.org/10.1111/jpc.15169

44. WHO. Guiding principles for immunization activities during the COVID-19 pandemic: interim guidance, 26 March 2020. World Health Organization; 2020. Available online: https://apps.who.int/iris/handle/10665/331590. Accessed on December 03, 2022.

45. WHO. Frequently asked questions (FAQ) immunization in the context of COVID-19 pandemic. In: World Health Organization. Available online: https://apps.who.int/iris/handle/10665/331818. Accessed on December 03, 2022.

46. COVID-19: Massive impact on lower-income countries threatens more disease outbreaks. Availabe online: https://www.gavi.org/news/media-room/covid-19-massive-impact-lower-income-countries-threatens-more-disease-outbreaks. Accessed on December 03, 2022.

47. Roberts L. Why measles deaths are surging — and coronavirus could make it worse. Nature. 2020;580(7804):446–447. https://doi.org/10.1038/d41586-020-01011-6

48. Mohapatra S, Venugopal SJ, Kalaivani M, et al. CAUTION-ED Study (Community-acquired UTI, Emerging Drug Resistance). Antibiotic resistance of uropathogens among the community-dwelling pregnant and nonpregnant female: a step towards antibiotic stewardship. BMC Infect Dis. 2022;22(1):939. https://doi.org/10.1186/s12879-022-07914-1

49. E Abou Warda A, Molham F, Salem HF, et al. Emergence of High Antimicrobial Resistance among Critically Ill Patients with Hospital-Acquired Infections in a Tertiary Care Hospital. Medicina (Kaunas). 2022;58(11):1597. https://doi.org/10.3390/medicina58111597

50. Lucien MAB, Canarie MF, Kilgore PE, et al. Antibiotics and antimicrobial resistance in the COVID-19 era: Perspective from resourcelimited settings. Int J Infect Dis. 2021;104:250–254. https://doi.org/10.1016/j.ijid.2020.12.087

51. Spernovasilis NA, Kofteridis DP. COVID-19 and antimicrobial stewardship: what is the interplay? Infect Control Hosp Epidemiol. 2021;42(3):378–379. https://doi.org/10.1017/ice.2020.246

52. Pal M, Muinao T, Parihar A, et al. Biosensors based detection of novel biomarkers associated with COVID-19: Current progress and future promise. Biosens Bioelectron X. 2022;12:100281. https://doi.org/10.1016/j.biosx.2022.100281

53. WHO policy guidance on integrated antimicrobial stewardship activities. Geneva: World Health Organization; 2021. Available online: https://www.who.int/publications-detail-redirect/9789240025530. Accessed on December 03, 2022.

54. May M, Chang M, Dietz D, et al. Limited Utility of Procalcitonin in Identifying Community-Associated Bacterial Infections in Patients Presenting with Coronavirus Disease 2019. Antimicrob Agents Chemother. 2021;65(4):02167–021620. https://doi.org/10.1128/AAC.02167-20

55. Wolfisberg S, Gregoriano C, Schuetz P. Procalcitonin for individualizing antibiotic treatment: an update with a focus on COVID-19. Crit Rev Clin Lab Sci. 2022;59(1):54–65. https://doi.org/10.1080/10408363.2021.1975637

56. WHO. Clinical management of COVID-19: interim guidance, 27 May 2020. World Health Organization; 2020. Available online: https://apps.who.int/iris/handle/10665/332196. Accessed on December 03, 2022.

57. Guidelines for management of COVID-19 in children (below 18 years). The Ministry of Health and Family Welfare, Government of India; 2021. Available online: https://www.mohfw.gov.in/pdf/GuidelinesforManagementofCOVID19inCHILDREN18June2021final.pdf. Accessed on December 03, 2022.

58. WHO. Antimicrobial stewardship programmes in health-care facilities in low-and middle-income countries: a WHO practical toolkit. Geneva: World Health Organization; 2019. Available online: https://apps.who.int/iris/handle/10665/329404. Accessed on December 03, 2022.

59. Luxi N, Giovanazzi A, Capuano A, et al. COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety. Drug Saf. 2021;44(12):1247–1269. https://doi.org/10.1007/s40264-021-01131-6

60. Frenck RW Jr, Klein NP, Kitchin N, et al. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. N Engl J Med. 2021;385(3):239–250. https://doi.org/10.1056/NEJMoa2107456

61. Swingler EA, Song M, Moore SE, et al. Fluoroquinolone stewardship at a community health system: A decade in review. Antimicrob Steward Healthc Epidemiol. 2022;2(1):e186. https://doi.org/10.1017/ash.2022.326

62. Saha SK, Thursky K, Kong DCM, Mazza D. A Novel GPPAS Model: Guiding the Implementation of Antimicrobial Stewardship in Primary Care Utilising Collaboration between General Practitioners and Community Pharmacists. Antibiotics (Basel). 2022;11(9):1158. https://doi.org/10.3390/antibiotics11091158.

63. Mak PHW, Rehman MA, Kiarie EG, et al. Production systems and important antimicrobial resistant-pathogenic bacteria in poultry: a review. J Anim Sci Biotechnol. 2022;13(1):148. https://doi.org/10.1186/s40104-022-00786-0.

64. Waters M, McKinnell JA, Kalil AC, et al. COVID-astegolimabinterleukin (IL) (COVASTIL) Study Group. Astegolimab or Efmarodocokin Alfa in Patients With Severe COVID-19 Pneumonia: A Randomized, Phase 2 Trial. Crit Care Med. 2023;51(1):103–116. https://doi.org/10.1097/CCM.0000000000005716

65. Hause AM, Gee J, Baggs J, et al. COVID-19 Vaccine Safety in Adolescents Aged 12–17 Years — United States, December 14, 2020-July 16, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(31):1053–1058. https://doi.org/10.15585/mmwr.mm7031e1

66. Pike J. India’s cumulative COVID-19 vaccination coverage exceeds 178.83 Cr. In: GlobalSecurity.org. March 06, 2022. Available online: https://www.globalsecurity.org/security/library/news/2022/03/sec-220306-india-pib01.htm. Accessed on December 03, 2022.

67. Doan VK, Tran CM, Ho TT, et al. Optimization of Oligomer Chitosan/Polyvinylpyrrolidone Coating for Enhancing Antibacterial, Hemostatic Effects and Biocompatibility of Nanofibrous Wound Dressing. Polymers (Basel). 2022;14(17):3541. https://doi.org/10.3390/polym14173541

68. Khan S, Bond SE, Bakhit M, et al. COVID-19 Mixed Impact on Hospital Antimicrobial Stewardship Activities: A Qualitative Study in UK-Based Hospitals. Antibiotics (Basel). 2022;11(11):1600. https://doi.org/10.3390/antibiotics11111600512

69. Owoicho O, Tapela K, Djomkam Zune AL, et al. Suboptimal antimicrobial stewardship in the COVID-19 era: is humanity staring at a postantibiotic future? Future Microbiol. 2021;16(12):919–925. https://doi.org/10.2217/fmb-2021-0008

70. EMA. First COVID-19 vaccine approved for children aged 12 to 15 in EU. In: European Medicines Agency. Science Medicines Health. Available online: https://www.ema.europa.eu/en/news/frst-covid-19-vaccine-approved-children-aged-12-15-eu. Accessed on December 03, 2022.

71. EMA. COVID-19 vaccine Spikevax approved for children aged 12 to 17 in EU. In: European Medicines Agency. Science Medicines Health. July 23, 2021. Available online: https://www.ema.europa.eu/en/news/covid-19-vaccine-spikevax-approvedchildren-aged-12-17-eu. Accessed on December 03, 2022.

72. Walter EB, Talaat KR, Sabharwal C, et al. Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age. N Engl J Med. 2022;386(1):35–46. https://doi.org/10.1056/NEJMoa2116298

73. CDC. COVID-19 vaccines for children and teens. In: Centers for Disease Control and Prevention. Update July 20, 2022. Available online: https://www.cdc.gov/coronavirus/2019ncov/vaccines/recommendations/children-teens.html. Accessed on December 03, 2022.

74. Тарасова А.А., Костинов М.П., Квасова М.А.. Вакцинация детей против новой коронавирусной инфекции и тактика иммунизации у пациентов с хроническими заболеваниями // Педиатрия. Журнал им. Г.Н. Сперанского. — 2021. — Т. 100. — № 6. —С. 15–22.

75. Gushchin VA, Dolzhikova IV, Shchetinin AM, et al. Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants. Vaccines (Basel). 2021;9(7):779. https://doi.org/10.3390/vaccines9070779